医学
结直肠癌
肿瘤科
内科学
诊断准确性
循环肿瘤DNA
采样(信号处理)
精密医学
临床实习
诊断试验
佐剂
辅助化疗
疾病
微小残留病
癌症
化疗
西妥昔单抗
分析灵敏度
局限性疾病
临床试验
荟萃分析
个性化医疗
梅德林
二元分析
一致性
辅助治疗
作者
Daniel G. Camblor,Belén Martínez-Castedo,Jorge Martín-Arana,Francisco Gimeno-Valiente,Blanca García-Micó,F. Martinez Martinez,Víctor Seguí,Miguel García-Bartolomé,Diego González,Alejandro Guimera,Marisol Huerta,Susana Roselló,Valentina Gambardella,Desamparados Roda,Leontios Pappas,Aparna Parikh,Juan Antonio Carbonell‐Asins,Andrès M.R. Cervantes,Noelia Tarazona
标识
DOI:10.1016/j.ctrv.2025.103066
摘要
In patients with early-stage colorectal cancer (CRC), circulating tumor DNA (ctDNA) testing is increasingly used to detect minimal residual disease (MRD) after curative-intent surgery. This information can guide decisions on adjuvant chemotherapy and surveillance. Two main approaches exist, tumor-informed (TI) and tumor-agnostic (TA), however, their diagnostic accuracy in clinical practice remains unclear. We conducted a bivariate diagnostic meta-analysis to compare sensitivity and specificity of TI versus TA ctDNA assays for detecting recurrence in patients with resected CRC. Subgroup analyses were performed based on landmark versus serial sampling strategies. In the serial-sampling setting, TI assays demonstrated markedly higher sensitivity than TA assays (0.88 vs. 0.59; p = 0.001), with no significant differences in false-positive rates. The landmark analyses did not show statistically significant differences between approaches. The results underscore the importance of sampling strategy when selecting a ctDNA test. When longitudinal monitoring is feasible, TI assays provide the most reliable detection of recurrence. This meta-analysis supports tailoring ctDNA testing to the clinical context, prioritizing TI approaches for serial surveillance to better guide adjuvant decision-making and improve patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI